developing-europe-header

DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio, followed by the Anaesthetics portfolio which is anticipated to become a significant contributor in this region.

Key Countries

The Czech Republic,
Poland,
Romania,
Russia,
Slovakia

Contribution to Group revenue

pic-9europe

Revenue contribution - by therapeutic category

pic-10europe
  • Injectable anticoagulants across Developing Europe & CIS grew by 2% in value as measured in Euros for the period ended 31 December 2018

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: Nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

Nil

3 – 5 years

Nil

Number of product recalls:

Nil

(2018: Nil)

Average staff turnover:

17,5%

(2018: 14,5%)

Number of work-related fatalities:

Nil

(2018: Nil)

Number of permanent employees:

june-05

Revenue2019
R'million
2017 (CER)
R'million
change
%
Total2 5162 810(10)
Regional Brands365438(17)
Sterile Focus Brands2 1512 372(9)
Anaesthetics Brands283411(31)
Thrombosis Brands1 8681 961 (5)